Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02485119 (Clinical Trial/ BAY94-9343)

Study Title
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies (NCT02485119)

Trial Description
The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors. The secondary objectives are to investigate the efficacy, biomarkers and immunogenicity. This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY94-9343
  • Phase: I
  • Estimated Enrollment: 15
  • Start: August 2015
  • Estimated Completion: November 2017
  • Last verified: June 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar